NLM Digital Collections

Search

Start Over Subjects Drug Costs ✖Remove constraint Subjects: Drug Costs Publication Year 2017 ✖Remove constraint Publication Year: <span class="single" data-blrl-single="2017">2017</span>

2. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

3. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

4. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system

5. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Medicaid -- economics
Pharmaceutical Preparations -- classification
Pharmaceutical Preparations -- economics
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

6. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):
Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author
Publication:
[New York, N.Y.] : Commonwealth Fund, July 2017
Subject(s):
Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
Drug Industry -- economics
Drugs, Generic -- economics
Economic Competition
Legislation, Drug
Orphan Drug Production -- economics
Humans
United States

7. No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending

Author(s):
Cubanski, Juliette, author
Neuman, Tricia, author
Orgera, Kendal, author
Damico, Anthony, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, November 2017
Subject(s):
Drug Costs
Financing, Personal
Health Expenditures
Medicare Part D -- economics
Medicare Part D -- trends
Chronic Disease -- drug therapy
Chronic Disease -- economics
Demography
Hepatitis C -- drug therapy
Leukemia -- drug therapy
Lymphoma -- drug therapy
Poverty
Humans
United States

9. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, November 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
Antitrust Laws
Biological Products -- economics
Drug Approval -- economics
Drug Development -- economics
Drug Development -- trends
Economic Competition
Forecasting
Orphan Drug Production -- economics
Taxes
Humans
United States
National Institutes of Health (U.S.)

10. Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, December 2017
Subject(s):
Drug Costs
Health Care Sector
Health Expenditures
Medicare Part B -- economics
Insurance, Health, Reimbursement
Medicare Part B -- statistics & numerical data
Humans
United States